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ABSTRACT
The strategy of treatment for patients with adrenal incidentalomas
(AI) may depend upon the presence of hormonal hypersecretion. Al-
though alterations of bone turnover have been recently reported, data
on bone mineral density (BMD) are not available in AI patients. We
evaluated bone turnover and BMD in 32 female AI patients and 64
matched controls. Spinal and femoral BMD were similar in patients
and controls. Serum bone GLA protein (6.8 6 3.5 vs. 8.8 6 3.2 ng/mL;
P , 0.005) and PTH (48.8 6 15.1 vs. 37.2 6 10.9 pg/mL; P , 0.0001)
were different in patients and controls. Patients were then subdivided
into 2 groups: with (n 5 8; group A) or without (n 5 24; group B)
subclinical hypercortisolism. PTH was higher (P , 0.05) in group A
than in group B and in both groups than in controls (57.1 6 13.6,
46.0 6 14.8, and 37.2 6 10.9 pg/mL, respectively), and bone GLA
protein was lower in group A than in group B and controls (3.8 6 2.3,
7.5 6 3.1, and 8.8 6 3.2 ng/mL, respectively; P , 0.05). Serum type
I cross-linked C telopeptide and fasting urinary deoxypyridinoline/
creatinine were not different in the three groups. BMD at each site
was lower (P , 0.05) in group A than in group B and controls. Bone
mass and metabolism are altered in AI patients with subclinical
hypercortisolism and should be taken into account, therefore, when
addressing the treatment of choice for these patients. (J Clin Endo-
crinol Metab 84: 2381–2385, 1999)
INCIDENTALLY discovered adrenal masses [adrenal in-cidentalomas (AI)] have recently become a relatively
common finding in patients evaluated by imaging tech-
niques for unrelated disorders (1–5). The strategy of treat-
ment for patients with AI is still under debate, and it may
depend also upon the presence of hormonal hypersecre-
tion. Although by definition AI are not associated with
clinically evident syndromes, up to 12% of these patients,
in fact, show biochemical signs of subclinical hypercorti-
solism (SH) (6 –11). Although it is well known that overt
glucocorticoid excess affects bone metabolism and mass
(12–16), the effect of SH on bone tissue is still not com-
pletely understood. Bone turnover has been recently stud-
ied in AI patients with a wide range of cortical adrenal
function (i.e. from normal to SH); bone apposition has been
consistently reported to be slightly, albeit significantly,
reduced (17, 18), whereas conflicting results have been
reported on bone resorption (17, 18). In contrast, no data
are available on bone mass in AI patients. This is not a
trivial lack of knowledge, because a reduction of bone
mineral density (BMD) would be an additional element to
be considered when addressing the treatment for these
patients. We present here data on bone turnover and mass
in 32 consecutive female AI patients, either with (n 5 8) or
without (n 5 24) SH. Data were compared to those ob-
tained in a group of 64 matched healthy subjects.
Subjects and Methods
Subjects
Thirty-two consecutive female patients with AI were studied. The
diagnosis of AI was made on the basis of 1) unilateral adrenal mass
detected during noninvasive methods of imaging of the abdomen per-
formed for unrelated diseases, and 2) lack of signs and/or symptoms of
hormonal hypersecretion. Only females were enrolled to avoid gender-
related confounding effects on the skeleton (19). Patients were then
subdivided into 2 groups: group A (n 5 8) and group B (n 5 24), with
and without SH, respectively. The diagnosis of SH was made on the basis
of increased 24-h urinary free cortisol (UFC) levels (.70 mg/24 h), the
cut-off of both our and international (20) normal reference values. Three
of 8 patients from group A showed unsuppressed morning serum cor-
tisol levels after a 1-mg overnight dexamethasone suppression test (F
after dex; .5 mg/dL). All patients from group A and 13 of 24 from group
B showed low ACTH levels (,10 pg/mL). Similar data have been
previously reported (21).
Age, body mass index, and menstrual status were not different be-
tween groups A and B (Table 1). In particular, mean menopause duration
was not different between the two groups (9.5 6 10.9 vs. 11.1 6 8.7).
Moreover, no patients in group A and only two patients in group B were
within the first 3 yr after the last menses.
No subject had evidence of neoplastic disease. At computed to-
mography, all lesions were homogeneous and hypodense and had
regular margins; these features are compatible with the diagnosis of
adrenocortical adenoma (5). The diameter of incidentalomas was not
different between group A and group B (mean 6 sd, 2.4 6 1.2 vs. 2.7 6
1.2 cm; range, 0.9 – 4.0 and 1.0 –5.5 cm, respectively). Three patients
(no. 5, 7, and 19 from group B in Table 2), who displayed diameters
of AI greater than 4 cm, had previously refused surgery. In all pa-
tients, no increase in adrenal mass was observed in a 12-month
follow-up. Pheochromocytoma and aldosteronoma were excluded by
appropriate hormonal measurements (24-h urinary catecholamines
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and PRA and aldosterone in the recumbent position and after 3 h of
orthostatic posture). Sixty-four healthy women, matched for age,
body mass index, and menstrual status, served as controls (Table 1).
Premenopausal women were studied in the early follicular phase
(days 3–7) of the menstrual cycle.
All subjects gave their witnessed informed consent before the study.
None of them was given medications known to affect bone metabolism,
including estrogen replacement therapy. Vertebral fractures were ex-
cluded in all subjects by lateral x-ray of the spine.
Methods
Serum and urinary samples were collected and stored at 270 C until
assayed. Serum total calcium (Ca), phosphorous (P), creatinine (Cr), and
alkaline phosphatase total activity were determined by a multichannel
autoanalyzer. Serum intact PTH levels were measured by a two-site
immunochemiluminometric assay (Chiron Diagnostics, East Walpole,
MA). Serum bone GLA protein (BGP) was assayed by immunoradio-
metric assay for the intact molecule [ELSA-OST-NAT, Cis Biointerna-
tional, Gif-sur-Yvette, France; intra- and interassay coefficients of vari-
ation (CVs), 3.8% and 4.7%, respectively]. Serum type I cross-linked C
telopeptide (ICTP) was measured by RIA (Orion Diagnostica, Espeo,
Finland; intra- and interassay CVs, 4.8% and 6.5%, respectively). Total
deoxypyridinoline on fasting spot urine corrected for creatinine excre-
tion (D-Pyr/Cr) was assessed, after reverse phase high performance
liquid chromatography, fluorometrically by kits from Bio-Rad Labora-
TABLE 2. Biochemical indexes of adrenal function in patients with adrenal incidentalomas
Patient no. F at 0800 h (mg/dL) F after dex (mg/dL) UFC (mg/24 h) ACTH (pg/mL)
Group A
1 6.2 0.7 102.8 7.1
2 14.5 1.0 113.0 7.7
3 10.4 2.5 86.5 5.7
4 11.6 1.7 73.6 4.4
5 24.0 9.9 104.0 8.8
6 16.8 7.4 317.0 1.7
7 17.8 13.3 73.0 3.0
8 16.0 1.4 95.0 9.0
Mean 6 SD 14.7 6 5.4 4.8 6 4.8 120.6 6 80.6a 5.9 6 2.7b
Group B
1 6.4 0.8 55.5 14.8
2 7.7 2.1 40.8 6.0
3 8.5 1.1 61.7 7.5
4 10.0 4.0 38.0 1.2
5 15.9 1.7 67.1 13.0
6 17.6 0.9 35.0 28.8
7 17.0 1.0 44.4 27.1
8 14.9 2.0 44.0 8.7
9 14.5 2.0 28.2 6.9
10 31.2 2.7 49.0 8.5
11 22.7 1.2 24.0 12.5
12 8.1 2.4 63.0 8.6
13 8.6 2.2 29.0 4.5
14 28.3 2.8 36.8 9.6
15 23.8 2.0 37.7 8.3
16 8.3 1.7 19.7 12.6
17 10.0 1.6 32.3 6.7
18 19.2 1.0 44.0 26.1
19 18.9 3.7 54.3 11.0
20 12.8 3.7 32.5 5.4
21 20.1 1.8 29.1 12.0
22 28.7 0.9 37.2 34.2
23 6.8 1.0 11.9 14.1
24 7.1 2.5 29.1 3.6
Mean 6 SD 15.3 6 7.6 2.0 6 0.9 40.6 6 17.4 12.1 6 8.5
Group A, Patients with subclinical hypercortisolism. Group B, Patients without subclinical hypercortisolism. F, Serum cortisol; normal
values: 7–25 mg/dL at 0800 h; F after dex, Serum cortisol at 0800 h after overnight 1 mg dexamethasone; normal values, less than 5 mg/dL.
UFC, Urinary free cortisol; normal values, less than 70 mg/24 h. ACTH, mean of three determinations at 0800; normal values, above 10 pg/mL.
a P , 0.0001 vs. group B.
b P , 0.05 vs. group B.
TABLE 1. Clinical characteristics of patients and controls
Controls (n 5 64)
Patients
All (n 5 32) Group A (n 5 8) Group B (n 5 24)
Age (yr) 56.4 6 12.3 (22–76) 56.5 6 12.4 (26–76) 54.0 6 18.4 (26–75) 57.3 6 10.0 (38–76)
BMI (kg/m2) 29.7 6 4.8 (21.5–45.0) 29.1 6 4.3 (21.9–40.0) 28.4 6 4.0 (21.9–33.2) 29.3 6 4.5 (22.3–40.0)
Gonadal status (pre/
postmenopausal)
16/48 8/24 4/4 4/20
Data are expressed as the mean 6 SD (range). Patients are presented either all together (All) or subdivided according to the presence (group
A) or the absence (group B) of subclinical hypercortisolism (see Materials and Methods).
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tories, Inc. (Segrate, Italy; intra- and interassay CVs, 6.6% and 12.3%,
respectively).
In all patients the following serum hormonal determinations were
performed at 0800 h: ACTH (mean of three determinations at 20-min
intervals), cortisol (F), and dehydroepiandrosterone sulfate (DHEAS). F
and UFC levels (after dichloromethanol extraction) were measured im-
munofluorometrically by TDX-FLX Abbott GmbH Diagnostika kits
(Wiesbaden-Delkenheim, Germany); serum ACTH and DHEAS levels
were measured by immunoradiometric assay (BRAHMS Diagnostica
GmbH, Berlin, Germany) and RIA (Diagnostics Systems Laboratories,
Inc., Webster, TX), respectively.
BMD was evaluated at both axial and appendicular skeletal sites, as
previously described (22). Spinal BMD was measured by both single
energy quantitative computed tomography L1–L4 (QCT; Toshiba CT
Xpeed, Toshiba Medical Systems Division, Tokyo, Japan), able to selec-
tively detect trabecular true density (in vivo precision, 1.8%), and dual
x-ray absorptiometry L2–L4 (DXA; Norland XR-26, Norland Instru-
ments, Fort Atkinson, WI), which assesses BMD of total vertebral bodies
(in vivo precision, 1.0%). BMD was also evaluated by dual x-ray ab-
sorptiometry at three femoral sites: neck (FN), Ward’s triangle, and great
trochanter (in vivo precision, 2.1%, 3.5%, and 2.4%, respectively). Indi-
vidual BMD values were expressed as sd units (z-values) in relation to
the reference population at our center (23).
Statistical analysis
The results are expressed as the mean 6 sd. For each variable, nor-
mality of distribution was tested by the W statistic of Shapiro-Wilk. Data
were compared by one-way ANOVA and either Bonferroni or Student-
Newman-Keuls test, as appropriate. The associations between variables
were tested by either Pearson or Spearman correlation, as appropriate.
P , 0.05 was considered significant.
Results
BMD measured at each site was not different between the
whole group of patients and controls (data not shown). In
contrast, BGP levels were lower, and PTH levels were higher
in patients than in controls [6.8 6 3.5 vs. 8.8 6 3.2 ng/mL (P ,
0.005) and 48.8 6 15.1 vs. 37.2 6 10.9 pg/mL (P , 0.0001),
respectively].
Hormonal data of patients from group A and B are sum-
marized in Table 2. By selection criterion, UFC levels were
significantly higher in group A. ACTH levels were also sig-
nificantly different, being lower in group A than in group B
(Table 2). F, both basally and after dexamethasone suppres-
sion, (Table 2), and DHEAS (data not shown) levels were not
different between the two groups.
Bone turnover data are shown in Table 3a. PTH levels were
significantly higher in group A than in group B and in both
groups than in controls. BGP levels were lower in group A
than in group B and controls. Alkaline phosphatase total
activity, ICTP, and D-Pyr/Cr (Table 3a) and serum Ca, P, and
creatinine (data not shown) did not significantly differ
among the three groups.
Spinal BMD, measured by both QCT and DXA, and fem-
oral BMD at each site were significantly lower in group A
than in group B and controls (Table 3b). No significant dif-
ference was found among the BMD reductions in each skel-
etal site in group A patients (Table 3b).
To evaluate the role of estrogens on the effect of glucocor-
ticoid excess on bone turnover and mass, BGP and BMD
z-values were separately compared for premenopausal
(group A, n 5 4; group B, n 5 4; controls, n 5 16) and
postmenopausal (group A, n 5 4; group B, n 5 20; controls,
n 5 48) subjects. Significant (P , 0.05) differences were
confirmed only in postmenopausal subjects (group A vs.
group B vs. controls: BGP, 2.6 6 0.6 vs. 7.7 6 3.3 vs. 9.3 6 3.3
ng/mL; DXA (L2–L4), 22.37 6 0.61 vs. 0.27 6 0.98 vs.
20.19 6 0.93; QCT (L1–L4), 21.77 6 0.75 vs. 20.01 6 1.08 vs.
20.3 6 0.89; Ward’s triangle, 21.83 6 0.90 vs. 2001 6 1.19
vs. 20.11 6 0.98; great trochanter, 21.80 6 1.06 vs. 0.25 6 1.07
vs. 0.06 6 0.98; FN, 22.24 6 0.21 vs. 0.04 6 1.07 vs. 20.04 6
0.87).
Correlations
In group A patients, but not in group B patients or controls,
PTH was significantly correlated directly with D-Pyr/Cr (r
TABLE 3a. PTH and bone turnover markers in group A, group B, and controls
Group A (n 5 8) Group B (n 5 24) Controls (n 5 64)
PTH (pg/mL) 57.1 6 13.6a 46.0 6 14.8a 37.2 6 10.9
AP (U/L) 207 6 104 190 6 70 167 6 43
BGP (ng/mL) 3.8 6 2.3a 7.5 6 3.1 8.8 6 3.2
ICTP (mg/L) 4.08 6 1.29 3.90 6 2.39 4.01 6 1.57
D-Pyr/Cr (pmol/pmol) 28.6 6 12.8 24.6 6 7.9 24.6 6 6.8
Data are expressed as the mean 6 SD. PTH, Serum intact PTH; AP, serum alkaline phosphatase total activity; BGP, serum bone Gla protein;
ICTP, serum type I cross-linked C telopeptide; D-Pyr/Cr, urinary deoxypyridinoline/creatinine.
a P , 0.05 vs. the other two groups.
TABLE 3b. BMD at different skeletal sites in group A, group B, and controls
Group A (n 5 8) Group B (n 5 24) Controls (n 5 64)
QCT (L1–L4) 21.02 6 1.29a 0.15 6 1.04 20.20 6 0.86
DXA (L2–L4) 21.37 6 1.26a 0.41 6 1.24 20.03 6 1.07
WT 21.31 6 1.16a 0.13 6 1.18 0.00 6 1.00
TR 20.99 6 1.16a 0.50 6 1.27 0.15 6 1.00
FN 21.34 6 1.08a 0.20 6 1.12 0.07 6 1.05
Data are the mean 6 SD of z-values. QCT, Lumbar vertebral trabecular spine L1–L4 bone mineral density. DXA, Lumbar vertebral integral
spine L2–L4 bone mineral density. WT, Ward’s triangle bone mineral density. TR, Femoral great trochanter bone mineral density. FN, femoral
neck bone mineral density. No statistically significant difference was found among the affected skeletal sites in group A.
a P , 0.05 vs. the other two groups.
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5 0.72; P , 0.05) and inversely with BMD measured at FN
(r 5 20.92; P , 0.002; Fig. 1).
Discussion
The aim of this study was to investigate whether the skel-
eton is affected in AI patients. For this purpose, BMD and
bone turnover in 32 consecutive female patients with AI were
evaluated. When comparing the whole group of patients to
matched controls, we found altered osteoblastic activity, as
reflected by reduced BGP levels, but normal bone resorption
and BMD at each site studied. After subdividing AI patients
into 2 groups according to the presence/absence of SH, we
found reduced BMD at each site and reduced BGP levels only
in the former group (group A). The negative effect of SH on
bone mass and apposition (BGP) was greater in postmeno-
pausal than in premenopausal patients. However, due to the
small number of observations, this has to be considered with
great caution.
Data on bone turnover, but not on BMD, have been pre-
viously reported in AI patients (17, 18). Our present finding
on bone apposition is in agreement with a recent report
showing reduced BGP in AI patients with SH (18). ICTP, a
marker of bone resorption, has been reported to be either
increased (17) or reduced (18). In our series, ICTP levels were
not different among the two groups of patients and controls.
Such conflicting results are possibly due to the low sensitivity
of the marker employed (24). To overcome this potential
problem, we also used a more sensitive marker of bone
resorption, such as D-Pyr/Cr (24), which was slightly, but
not significantly, increased in group A patients. At variance
with previous studies (17, 18), we also measured PTH levels
in AI patients. Similar to patients with Cushing’s syndrome
(16), subjects with AI showed a picture of secondary hyper-
parathyroidism, the degree of which was significantly higher
in group A (with SH) than in group B (without SH).
In this study, BMD was assessed in AI patients and was
reduced in those with SH. In our opinion, the finding of
reduced bone mass in AI patients with SH is of immediate
clinical relevance; the risk of osteoporosis may be, in fact, an
additional element to be considered when addressing the
treatment of choice in these patients.
At variance with patients with Cushing’s syndrome, in
which trabecular bone at lumbar spine is predominantly
affected (16), AI patients with SH showed a similar degree of
BMD reduction at various skeletal sites. It can be hypothe-
sized that, in contrast to patients with Cushing’s syndrome,
in whom the overt glucocorticoid excess obscures the neg-
ative effect of high PTH levels, in AI patients the effects of
a low degree of glucocorticoid excess and of hyperparathy-
roidism on trabecular and cortical bone, respectively, are of
the same degree. Moreover, a cause-effect relationship be-
tween PTH and decreased cortical bone mass in AI patients
with SH is suggested by the negative correlation between
PTH levels and BMD measured at FN.
After ruling out the possibility of a primary or metastatic
malignant lesion, a central point in the management of AI
smaller than 4–6 cm is whether such tumors deserve surgical
excision (5, 25–29). This decision may depend on the presence
of several variables; among others, the presence of glucocor-
ticoid excess complications, including reduction of bone
mass and altered bone metabolism, have to be considered. In
this regard, our data indicate that AI patients with SH are at
risk of osteoporosis. Bone mass and metabolism should,
therefore, be evaluated and taken into account when ad-
dressing the treatment of choice for these patients.
FIG. 1. Correlation between femoral
neck BMD and PTH values in patients
with subclinical hypercortisolism
(group A).
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